PE20030340A1 - Metodo para el tratamiento o prevencion de desgaste oseo - Google Patents

Metodo para el tratamiento o prevencion de desgaste oseo

Info

Publication number
PE20030340A1
PE20030340A1 PE2002000815A PE2002000815A PE20030340A1 PE 20030340 A1 PE20030340 A1 PE 20030340A1 PE 2002000815 A PE2002000815 A PE 2002000815A PE 2002000815 A PE2002000815 A PE 2002000815A PE 20030340 A1 PE20030340 A1 PE 20030340A1
Authority
PE
Peru
Prior art keywords
antihuman
treatment
antihumanetic
hfe7a
antibody
Prior art date
Application number
PE2002000815A
Other languages
English (en)
Inventor
Yukie Ogama
Chie Fukida
Masahiko Ohisuki
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of PE20030340A1 publication Critical patent/PE20030340A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION PARA EL TRATAMIENTO DE DESGASTE OSEO OCASIONADO POR UNA ENFERMEDAD QUE ACTIVA OSTEOCLASTOS COMO ARTRITIS REUMATOIDE QUE COMPRENDE UN VEHICULO O DILUYENTE, ANTICUERPO MONOCLONAL Fas ANTIHUMANO HFE7A, UN ANTICUERPO MONOCLONAL Fas ANTIHUMANO HFE7A HUMANIZADO, ANTIINFLAMATORIOS NO ESTEROIDEOS (DICLOFENACO, LOXOPROFEN, CELECOXIB, ETODOLAC, MELOXICAM, ROFECOXIB, PIROXICAM, ENTRE OTROS); ANTIRREUMATICOS, INTERFERON GAMMA, COMPUESTOS CON ACTIVIDAD ANTAGONISTA A FOLATO, ANTAGONISTA A DIHIDROFOLATO COMO METOTREXATO, EDATREXATO, EPIROPRIM, IOMETREXOL, ENTRE OTROS. TAMBIEN SE REFIERE A FAS ANTIHUMANO ELABORADO MEDIANTE TECNOLOGIA RECOMBINANTE A PARTIR DE UNA CADENA LIGERA HUMANIZADA Y UNA CADENA PESADA OBTENIDA DE PLASMIDO RECOMBINANTES PORTADOS POR CEPAS TRANSFORMADAS DE E COLI
PE2002000815A 2001-08-28 2002-08-26 Metodo para el tratamiento o prevencion de desgaste oseo PE20030340A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001257436 2001-08-28

Publications (1)

Publication Number Publication Date
PE20030340A1 true PE20030340A1 (es) 2003-04-05

Family

ID=19085098

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000815A PE20030340A1 (es) 2001-08-28 2002-08-26 Metodo para el tratamiento o prevencion de desgaste oseo

Country Status (6)

Country Link
EP (1) EP1421118A1 (es)
AR (1) AR036305A1 (es)
CA (1) CA2458993A1 (es)
PA (1) PA8553901A1 (es)
PE (1) PE20030340A1 (es)
WO (1) WO2003020768A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
US20050032807A1 (en) * 2003-08-06 2005-02-10 Rosenwald Lindsay A. Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives
AU2009277824B2 (en) * 2008-08-01 2013-06-06 Axis Inc. Therapeutic agent or preventive agent for osteoarthritis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201333A3 (en) * 1999-05-24 2004-11-29 Sankyo Company Ltd Chuo Ku Medicinal compositions containing anti-fas antibody

Also Published As

Publication number Publication date
WO2003020768A1 (en) 2003-03-13
CA2458993A1 (en) 2003-03-13
PA8553901A1 (es) 2003-06-30
AR036305A1 (es) 2004-08-25
EP1421118A1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
ECSP044978A (es) ANTICUERPOS HUMANOS ANTAGONISTAS CONTRA hTNFSF13b
MX2023007748A (es) Sintesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras.
PE20120429A1 (es) Proteinas de enlace de miostatina
NL301089I2 (nl) imlifidase
ATE428731T1 (de) Therapeutische antiköper mit reduzierten nebenwirkungen
CU20200014A7 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
CR9975A (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
AR061568A1 (es) Compuestos
CY1109662T1 (el) Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασης
RS54468B1 (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
AR041374A1 (es) Derivados de 2-oxodihidropiridina n- sustituidos
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
BRPI0314814B8 (pt) anticorpo compreendendo uma variante de fc
PE20141162A1 (es) Anticuerpos anti-il-23
NO20030896D0 (no) Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler
PA8610601A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
DK1937721T3 (da) Anti-IL-23 antistoffer
TW200741134A (en) Optical device for creating an illumination window
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
PE20211708A1 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r
PE20220708A1 (es) Anticuerpos anti-cd73
BR9908928A (pt) Catalisadores de complexos de cianetos metálicos duplos modificados com compostos de cálcio

Legal Events

Date Code Title Description
FA Abandonment or withdrawal